Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 26.7% in May

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 43,900 shares, a decline of 26.7% from the April 30th total of 59,900 shares. Based on an average daily trading volume, of 212,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company's stock are sold short.

Xtant Medical Stock Up 2.1%

Shares of NYSEAMERICAN:XTNT traded up $0.01 during trading on Wednesday, reaching $0.69. 639 shares of the company traded hands, compared to its average volume of 120,994. The firm has a fifty day simple moving average of $0.53 and a 200 day simple moving average of $0.52. The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. Xtant Medical has a 1-year low of $0.33 and a 1-year high of $0.83. The firm has a market cap of $95.92 million, a P/E ratio of -5.31 and a beta of 0.35.

Hedge Funds Weigh In On Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Renaissance Technologies LLC increased its position in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 798,033 shares of the medical device company's stock after acquiring an additional 103,825 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Xtant Medical worth $354,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 69.33% of the company's stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.